MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.06
+0.45
+1.11%
After Hours: 40.85 -0.21 -0.50% 16:11 12/06 EST
OPEN
40.87
PREV CLOSE
40.61
HIGH
41.36
LOW
40.37
VOLUME
235.48K
TURNOVER
--
52 WEEK HIGH
46.33
52 WEEK LOW
27.75
MARKET CAP
2.33B
P/E (TTM)
69.38
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XNCR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XNCR News

  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.17h ago
  • Xencor (XNCR) Presents At Jefferies 2019 London Healthcare Conference - Slideshow
  • Seeking Alpha - Article.3d ago
  • Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 44% Discount?
  • Simply Wall St..11/19 17:58
  • Drug Legislation Likely to Dry Up Biotech Funding
  • GuruFocus.com.11/19 15:33

More

Industry

Biotechnology & Medical Research
+0.66%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About XNCR

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
More

Webull offers Xencor Inc (XNCR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.